Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

Will the alternative become a leader?

October 1, 2009

Analysis of:EMEA recommends approval of Sanofi-aventis' dronedarone for atrial fibrillation | www.pharmabiz.com

Introducing dronedarone in treatment of atrial fibrillation will provide solution for many patients with atrial fibrillation who were undertreated due to their contraindications for amiodarone or it's adverse effects.

Convenient for patients, and maybe for doctors

September 26, 2009

Analysis of:Novartis gets FDA approval for combo pill valturna to treat high BP | www.pharmabiz.com

Undoubtedly powerful combination which will help control BP in many patients who have resistant or difficult to control hypertension.

Good idea in a large company

September 14, 2009

Analysis of:Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com

Good ideas and good products are better improved and marketed as a products of a large company, but....

Long expected new breakthrough

March 2, 2009

Analysis of:NEJM Publishes Results From The Landmark ATHENA Trial With Multaq(R) (dronedarone) In Atrial Fibrillation | www.medicalnewstoday.com

Dronedarone will probably replace amiodarone and maybe some other antiarrhythmics drugs. Unfortunately, the question of its application in heart failyre will have to be answered in the following years

Shadows casted over "to-be" blockbuster drug

March 2, 2009

Analysis of:F.D.A. Panel Endorses Lilly Blood Thinner | www.nytimes.com

Prasugrel as a novel drug which was supposed to replace Plavix, especially amid proofs of clopidogrel resistance, interactions with some common drugs such as PPI's, might not do so. Inspite great expectations it might become a potent drug with limited use due to not so acceptable side effect.

Opening the Pandora's box again?

November 27, 2008

Analysis of:New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug | pharmalive.com

Certain number of patients taking clopidogrel have GI complications as well. Limiting the use of PPI's in those patients limits their treatment and prevention of GI complications.

Page : 11 to 6 of 6

Request a News Analysis

Subscribe to Updates

By RSS